Kainova Therapeutics is the new name of Domain Therapeutics.
The company said its new name and brand reflect its “clinical momentum, global focus, and readiness for the next chapter of strategic growth, anchored by a mature pipeline of G protein-coupled receptor (GPCR)-modulating therapies.”
Kainova combines kairos, an opportune or decisive moment, and nova, to symbolise innovation and renewal.
“The rebrand is not a break from our scientific or strategic roots,” said Sean A. MacDonald, chief executive officer of Kainova Therapeutics.
“It is the clearer expression of who we are today and the impact we strive to deliver for patients. It highlights a continuation between our past successes and the growth path we envision for the future. Above all, Kainova Therapeutics embodies our belief that better is always possible.”
Kainova is advancing clinically differentiated therapies designed to unlock the untapped potential of GPCRs. The company’s lead programmes include DT-7012, a Treg-depleting anti-CCR8 antibody with competitive properties in phase I/II trials for solid tumours, DT-9046, a first-in-modality, pre-IND biased PAR2 antagonist in inflammation, and DT-9081, a phase II-ready EP4 receptor antagonist for solid tumours.
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.